Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Actinium Pharmaceuticals (DE:7AY1)
FRANKFURT:7AY1
RESEARCH TOOLSreports
Actinium Pharmaceuticals (7AY1) Stock Price & Analysis
0 Followers
7AY1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€3.60 - €8.67
Previous Close€6.34
Volume0.00
Average Volume (3M)925.00
Market Cap
€197.81M
Enterprise Value€135.36M
Total Cash (Recent Filing)$76.68M
Total Debt (Recent Filing)$10.07M
Price to Earnings (P/E)N/A
Beta0.48
Next Earnings
Mar 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,396,411
10 Day Avg. Volume326
30 Day Avg. Volume925
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)5.54
Price to Sales (P/S)2226.51
Price to Cash Flow (P/CF)-6.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.67K
Enterprise Value/Gross Profit1.67K
Enterprise Value/Ebitda-4.92
Forecast
1Y Price Target
€28.59Price Target Upside350.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Actinium Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial StabilityActinium's extended cash runway into the second half of 2026 reduces near-term financial risk for investors.
Market Expansion And PartnershipsActinium's partnership with Immedica for Iomab commercialization could pave the way for market expansion in Europe, Middle East, and North Africa.
Strategic Investment And Cost EfficiencyActinium announces a strategic investment in a cyclotron-based method for high-purity Actinium-225 production, potentially leading to significantly lower costs than current market prices.
Bears Say
Financial PerformanceActinium filed its 10-K, reporting 4Q23 results with a net loss of ($48.8M).
Market OpportunityPatients over 65 years old face a challenging outlook, often making allo-HCT less feasible due to increased non-relapse mortality and existing health issues.
Stock ValuationPrice Target lowered from $20 to $16 due to delayed commercial launch of Iomab-B to 2025.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors
7AY1 FAQ
What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was €3.60 and its highest was €8.67 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Currently, no data Available
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s upcoming earnings report date is Mar 14, 2025 which is in 325 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Actinium Pharmaceuticals released its earnings results on Mar 15, 2024. The company reported -€0.319 earnings per share for the quarter, beating the consensus estimate of -€0.534 by €0.216.
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actinium Pharmaceuticals have?
Currently, no data Available
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Actinium Pharmaceuticals reported an EPS of -€0.319 in its last earnings report, beating expectations of -€0.534. Following the earnings report the stock price went down -5.738%.
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Among the largest hedge funds holding Actinium Pharmaceuticals’s share is Royce & Associates LLC. It holds Actinium Pharmaceuticals’s shares valued at 254K.
---
Actinium Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€28.59 (350.92% Upside)
€28.59 (350.92% Upside)
Blogger Sentiment
Bullish
DE:7AY1 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.90%
12-Months-Change
Fundamentals
Return on Equity
-94.92%
Trailing 12-Months
Asset Growth
-28.68%
Trailing 12-Months
Company Description
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.
---
7AY1 Stock 12 Months Forecast
Average Price Target
€28.59
▲(350.92% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Bio-Path Holdings
―
Heron Therapeutics
―
Kura Oncology
―
MacroGenics
―
Best Analysts Covering 7AY1
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
-4.32%
reiterated a buy rating 23 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of -4.32% per trade.
---